Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00762736 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Type 2 Diabetes Mellitus
A Phase 2 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 2
- Development phase
- 704
- Enrollment target
NCT00762736: Completed Phase 2 study, sponsored by Takeda.
NCT00762736 is a Phase 2 study that has completed, run by Takeda. The registered enrollment target is 704 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (429% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00762736, a Phase 2 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 704 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy of pioglitazone, once daily (QD), combined with azilsartan in the treatment of subjects with Type 2 Diabetes Mellitus.
Interventions
- DRUG Pioglitazone
- DRUG Pioglitazone and azilsartan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 704 participants |
| Start Date | 2004-07 |
| Est. Completion | 2005-10 |
| Phase | Phase 2 |
What the finished NCT00762736 record still lists
NCT00762736 is an interventional study that assigns participants to a tested intervention. The registered 704 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (429% higher).
The record links to 0 conditions, and to 2 interventions - of which Pioglitazone is the first listed.
NCT00762736 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00762736 about?
NCT00762736 is a clinical study titled "Efficacy and Safety of Pioglitazone and Azilsartan in Treating Subjects With Type 2 Diabetes Mellitus". The purpose of this study is to determine the efficacy of pioglitazone, once daily (QD), combined with azilsartan in the treatment of subjects with Type 2 Diabetes Mellitus.
What is the current status of trial NCT00762736?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 704 participants. The study started on 2004-07. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00762736?
The interventions under investigation include: Pioglitazone (DRUG), Pioglitazone and azilsartan (DRUG).
Who is sponsoring clinical trial NCT00762736?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00762736's enrollment target sits among peer trials
704 46th of 2000 higher than 1,955 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05796687 · 704 participants · NA
Evaluation of My Future Self, an New Teen Pregnancy Prevention Group Intervention for Youth in Non-traditional Settings
- NCT06350734 · 704 participants
Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study
- NCT06480383 · 705 participants · Phase 2
Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
- NCT07067463 · 705 participants · Phase 3
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia